316 related articles for article (PubMed ID: 15267230)
1. Novel 2-aminotetralin and 3-aminochroman derivatives as selective serotonin 5-HT7 receptor agonists and antagonists.
Holmberg P; Sohn D; Leideborg R; Caldirola P; Zlatoidsky P; Hanson S; Mohell N; Rosqvist S; Nordvall G; Johansson AM; Johansson R
J Med Chem; 2004 Jul; 47(16):3927-30. PubMed ID: 15267230
[TBL] [Abstract][Full Text] [Related]
2. Structure-affinity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinealkylamides, a new class of 5-hydroxytryptamine7 receptor agents.
Leopoldo M; Berardi F; Colabufo NA; Contino M; Lacivita E; Niso M; Perrone R; Tortorella V
J Med Chem; 2004 Dec; 47(26):6616-24. PubMed ID: 15588097
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of new serotonin 5-HT7 receptor ligands. Determinants of 5-HT7/5-HT1A receptor selectivity.
Medina RA; Sallander J; Benhamú B; Porras E; Campillo M; Pardo L; López-Rodríguez ML
J Med Chem; 2009 Apr; 52(8):2384-92. PubMed ID: 19326916
[TBL] [Abstract][Full Text] [Related]
4. New benzo[h][1,6]naphthyridine and azepino[3,2-c]quinoline derivatives as selective antagonists of 5-HT4 receptors: binding profile and pharmacological characterization.
Hinschberger A; Butt S; Lelong V; Boulouard M; Dumuis A; Dauphin F; Bureau R; Pfeiffer B; Renard P; Rault S
J Med Chem; 2003 Jan; 46(1):138-47. PubMed ID: 12502367
[TBL] [Abstract][Full Text] [Related]
5. 2,3-Dihydro-2-oxo-1H-benzimidazole-1-carboxamides with selective affinity for the 5-HT(4) receptor: synthesis and structure-affinity and structure-activity relationships of a new series of partial agonist and antagonist derivatives.
Tapia I; Alonso-Cires L; López-Tudanca PL; Mosquera R; Labeaga L; Innerárity A; Orjales A
J Med Chem; 1999 Jul; 42(15):2870-80. PubMed ID: 10425096
[TBL] [Abstract][Full Text] [Related]
6. The selective 5-HT1B receptor inverse agonist 1'-methyl-5-[[2'-methyl-4'-(5-methyl-1,2, 4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro- spiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo.
Gaster LM; Blaney FE; Davies S; Duckworth DM; Ham P; Jenkins S; Jennings AJ; Joiner GF; King FD; Mulholland KR; Wyman PA; Hagan JJ; Hatcher J; Jones BJ; Middlemiss DN; Price GW; Riley G; Roberts C; Routledge C; Selkirk J; Slade PD
J Med Chem; 1998 Apr; 41(8):1218-35. PubMed ID: 9548813
[TBL] [Abstract][Full Text] [Related]
7. 3-(Arylsulfonyl)-1-(azacyclyl)-1H-indoles are 5-HT(6) receptor modulators.
Bernotas RC; Antane S; Shenoy R; Le VD; Chen P; Harrison BL; Robichaud AJ; Zhang GM; Smith D; Schechter LE
Bioorg Med Chem Lett; 2010 Mar; 20(5):1657-60. PubMed ID: 20138763
[TBL] [Abstract][Full Text] [Related]
8. Cycloalkanecarboxylic esters derived from lysergol, dihydrolysergol-I, and elymoclavine as partial agonists and antagonists at rat 5-HT2A receptors: pharmacological evidence that the indolo[4,3-fg]quinoline system of the ergolines is responsible for high 5-HT2A receptor affinity.
Pertz HH; Milhahn H; Eich E
J Med Chem; 1999 Feb; 42(4):659-68. PubMed ID: 10052973
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and serotonergic activity of 3-[2-(pyrrolidin-1-yl)ethyl]indoles: potent agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B receptor.
Sternfeld F; Guiblin AR; Jelley RA; Matassa VG; Reeve AJ; Hunt PA; Beer MS; Heald A; Stanton JA; Sohal B; Watt AP; Street LJ
J Med Chem; 1999 Feb; 42(4):677-90. PubMed ID: 10052975
[TBL] [Abstract][Full Text] [Related]
10. Medicinal chemistry driven approaches toward novel and selective serotonin 5-HT6 receptor ligands.
Holenz J; Mercè R; Díaz JL; Guitart X; Codony X; Dordal A; Romero G; Torrens A; Mas J; Andaluz B; Hernández S; Monroy X; Sánchez E; Hernández E; Pérez R; Cubí R; Sanfeliu O; Buschmann H
J Med Chem; 2005 Mar; 48(6):1781-95. PubMed ID: 15771424
[TBL] [Abstract][Full Text] [Related]
11. Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy of arylpiperazine derivatives at the central 5-HT3 receptors.
Cappelli A; Anzini M; Vomero S; Canullo L; Mennuni L; Makovec F; Doucet E; Hamon M; Menziani MC; De Benedetti PG; Bruni G; Romeo MR; Giorgi G; Donati A
J Med Chem; 1999 May; 42(9):1556-75. PubMed ID: 10229626
[TBL] [Abstract][Full Text] [Related]
12. Conformationally constrained N1-arylsulfonyltryptamine derivatives as 5-HT6 receptor antagonists.
Cole DC; Lennox WJ; Stock JR; Ellingboe JW; Mazandarani H; Smith DL; Zhang G; Tawa GJ; Schechter LE
Bioorg Med Chem Lett; 2005 Nov; 15(21):4780-5. PubMed ID: 16125933
[TBL] [Abstract][Full Text] [Related]
13. 5-HT1B receptor antagonist properties of novel arylpiperazide derivatives of 1-naphthylpiperazine.
Jorand-Lebrun C; Pauwels PJ; Palmier C; Moret C; Chopin P; Perez M; Marien M; Halazy S
J Med Chem; 1997 Nov; 40(24):3974-8. PubMed ID: 9397179
[TBL] [Abstract][Full Text] [Related]
14. Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7).
Glennon RA
J Med Chem; 2003 Jul; 46(14):2795-812. PubMed ID: 12825922
[No Abstract] [Full Text] [Related]
15. Novel 3-aminochromans as potential pharmacological tools for the serotonin 5-HT(7) receptor.
Holmberg P; Tedenborg L; Rosqvist S; Johansson AM
Bioorg Med Chem Lett; 2005 Feb; 15(3):747-50. PubMed ID: 15664850
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2.
Leopoldo M; Lacivita E; Contino M; Colabufo NA; Berardi F; Perrone R
J Med Chem; 2007 Aug; 50(17):4214-21. PubMed ID: 17649988
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotonin 5-HT3 and dopamine D2 receptor antagonistic activity.
Hirokawa Y; Fujiwara I; Suzuki K; Harada H; Yoshikawa T; Yoshida N; Kato S
J Med Chem; 2003 Feb; 46(5):702-15. PubMed ID: 12593651
[TBL] [Abstract][Full Text] [Related]
18. 8-Piperazinyl-2,3-dihydropyrrolo[3,2-g]isoquinolines: potent, selective, orally bioavailable 5-HT1 receptor ligands.
Heightman TD; Gaster LM; Pardoe SL; Pilleux JP; Hadley MS; Middlemiss DN; Price GW; Roberts C; Scott CM; Watson JM; Gordon LJ; Holland VA; Powles J; Riley GJ; Stean TO; Trail BK; Upton N; Austin NE; Ayrton AD; Coleman T; Cutler L
Bioorg Med Chem Lett; 2005 Oct; 15(19):4370-4. PubMed ID: 16039851
[TBL] [Abstract][Full Text] [Related]
19. Benzylimidazolines as h5-HT1B/1D serotonin receptor ligands: a structure-affinity investigation.
Law H; Dukat M; Teitler M; Lee DK; Mazzocco L; Kamboj R; Rampersad V; Prisinzano T; Glennon RA
J Med Chem; 1998 Jun; 41(13):2243-51. PubMed ID: 9632357
[TBL] [Abstract][Full Text] [Related]
20. Novel 1-(azacyclyl)-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines as 5-HT6 agonists and antagonists.
Elokdah H; Li D; McFarlane G; Bernotas RC; Robichaud AJ; Magolda RL; Zhang GM; Smith D; Schechter LE
Bioorg Med Chem; 2007 Sep; 15(18):6208-26. PubMed ID: 17624788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
